Paul Scigalla
Chief Tech/Sci/R&D Officer chez GENELUX CORPORATION
Profil
Paul Scigalla is currently the Chief Medical Officer at Genelux Corp.
since 2011 and a Professor at Ruprecht-Karls-Universität Heidelberg since 1992.
He was previously the Executive Vice President at Sugen, Inc. from 1998 to 2001.
He also held the position of Chief Medical Officer at Nuevolution AB and Deutsche Biotech Innovativ AG.
Scigalla obtained his doctorate degree from Humboldt-Universität zu Berlin.
Postes actifs de Paul Scigalla
| Sociétés | Poste | Début |
|---|---|---|
| GENELUX CORPORATION | Chief Tech/Sci/R&D Officer | 01/09/2011 |
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 01/01/1992 |
Anciens postes connus de Paul Scigalla
| Sociétés | Poste | Fin |
|---|---|---|
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2001 |
| NUEVOLUTION AB (PUBL) | Chief Tech/Sci/R&D Officer | - |
| DEUTSCHE BIOTECH INNOVATIV AG | Chief Tech/Sci/R&D Officer | - |
Formation de Paul Scigalla
| Humboldt-Universität zu Berlin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GENELUX CORPORATION | Health Technology |
| DEUTSCHE BIOTECH INNOVATIV AG | Finance |
| Entreprise privées | 2 |
|---|---|
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
